Dermata Therapeutics, Inc. Warrant
DRMAW
About: Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
Employees: 8
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding
Funds holding: 3 [Q1] → 4 (+1) [Q2]
0.91% more ownership
Funds ownership: 1.1% [Q1] → 2.02% (+0.91%) [Q2]
45% less capital invested
Capital invested by funds: $13.2K [Q1] → $7.29K (-$5.95K) [Q2]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Financial journalist opinion
We haven’t received any recent news articles for DRMAW